Approval Background

The EMA officially approved epcoritamab on September 22, 2023. This approval is based on the safety and efficacy demonstrated in clinical trials. In particular, this bispecific antibody, which simultaneously targets CD3 and CD20, showed a higher response rate compared to existing treatments. These results contribute to expanding treatment options for patients.

Competitive Positioning

Epcoritamab has a mechanism of action that differentiates it from existing CD20 single-target antibodies. Compared to existing treatments, it is expected to provide faster tumor cell removal and sustained immune activation. Therefore, it is likely to establish itself as a new standard treatment in the B-cell malignancy market.

Insurance Coverage and Market Entry Limitations

Price negotiations are underway throughout Europe, and the reimbursement decisions of each country's health authorities will affect future market expansion. In particular, cost-effectiveness analysis is required for high-priced treatments, so it may take time to secure initial reimbursement. However, if the treatment effect is clear, the possibility of reimbursement approval increases.

Market Size and Outlook

Although the original text does not specify the market size, the market for B-cell malignancy treatments is showing continuous growth. The newly approved drug is expected to reshape the existing market and create additional revenue opportunities. Therefore, the long-term revenue growth potential of epcoritamab can be seen as positive.